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More	than	50%	of	patients	with	cancer	require	ra-
diation	as	adjuvant	or	palliative	treatment.	Combining	
radiation	with	cytotoxic	chemotherapeutic	agents	has	
become	common	practice.	However,	 little	 is	known	
about	the	 interactions	of	the	novel	antitumor	drugs,	
such	as	STI-571,	with	standard	treatment	[1–4].
STI-571	 (imatinib	mesylate;	Gleevec)	has	been	
found	to	be	effective	in	the	treatment	of	chronic	myeloid	
leukemia	 (CML)	and	gastrointestinal	stromal	 tumors	
[5–9].	In	CML,	it	exerts	its	antitumor	action	by	inhibiting	
the	phosphorylation	of	downstream	proteins	involved	
in	BCR-ABL	signal	transduction.	STI-571	also	affects	
receptor	 tyrosine	kinases,	namely	c-kit	and	platelet-
derived	growth	factor	(PDGF)	receptors	[10].	
The	effect	of	 the	 interaction	of	STI-571	and	 ra-
diation	on	Abl-expressing	cells	remains	unclear.	One	
study	found	that	fibroblasts	from	Abl	knockout	mice	
have	 reduced	sensitivity	 to	 ionizing	 radiation	 [11],	
whereas	later	reports	contradicted	this	result	[2].	To	
explain	the	possible	interaction	between	radiation	and	
STI-571,	some	authors	suggested	that	STI-571	may	
be	involved	in	the	inhibition	of	Rad	51	expression.	Rad	
51	is	a	component	of	the	DNA	repair	pathway,	and	its	
reduction	would	be	expected	 to	enhance	 radiation	
sensitivity	 [12,	13].	However,	 although	STI-571	 re-
duced	Rad	51	levels	in	glioma	cells,	it	was	unable	to	
completely	eliminate	the	radiation-induced	increase	
in	Rad	51,	suggesting	the	presence	of	an	additional	
signaling	process	[3].	
The	activation	of	the	phosphatidylinositol	3	kinase	
(PI3K)/AKT	signal	 transduction	pathway	may	be	a	
major	contributor	to	radioresistance	as	well	as	to	cis-
platin	resistance	[14,	15].	AKT,	the	key	protein	in	this	
pathway,	was	 reported	 to	be	 involved	 in	enhancing	
cell	proliferation	and	inhibiting	apoptosis	[16].	Thus,	
the	(PI3K)/AKT	pathway	is	a	promising	target	for	novel	
anticancer	agents.
In	 the	present	study,	we	examined	 the	effect	of	
combined	 treatment	with	STI-571	and	 radiation	or	
cisplatin	on	SKNMC,	a	cell	 line	derived	 from	Ewing	
sarcoma,	and	on	 the	human	MCF-7	breast	cancer	
cell	line.	SKNMC	is	characterized	by	overexpression	
of	the	c-kit	receptor	[17],	whereas	MCF-7	cells	exhibit	
low	c-kit-receptor	expression.	Both	cell	lines	display	
radiation	sensitivity.
Materials and Methods
STI-571	was	kindly	donated	by	Novartis	Pharma-
ceutical	Inc.	(Basel,	Switzerland).	Sulforhodamine	B	
(SRB)	was	obtained	from	Sigma	(St.	Louis,	MO).	RPMI	
1640,	fetal	calf	serum	(FCS)	and	antibiotics	(penicillin	
and	streptomycin)	were	purchased	 from	Biological	
Industries	(Beth	Ha’Emek,	Israel).	The	chemothera-
peutic	agent	cisplatin	(Abiplatin)	was	obtained	from	
ABIC	(Netanya,	Israel).
Cell cultures.	The	SKNMC	cell	line,	derived	from	
peripheral	 primitive	 neuroectodermal	 tumor,	was	
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kindly	donated	by	Dr.	Gad	Lavie,	Sheba	Medical	Cen-
ter,	Israel.	MCF-7,	a	human	breast	cancer	cell	line,	was	
purchased	from	ATCC.	Both	cell	lines	were	cultured	in	
RPMI	1640	supplemented	with	10%	FCS	and	antibiot-
ics	(penicillin,	streptomycin).	The	cells	were	incubated	
at	37		°C	in	a	5%	CO2,	95%	humidified	atmosphere.	
Incubation	of	 the	SKNMC	or	MCF-7	cells	 in	 the	
presence	of	increasing	concentrations	of	STI-571	(0,	5,	
10,	15,	20	µM)	for	5	days	was	performed	to	determine	
the	concentration	of	STI-571	required	to	cause	a	50%	
decrease	in	cell	number	(IC50).	
Cytotoxicity assay.	Cells	 (1.5	 x	 104/ml)	were	
seeded	in	quadruplicate	in	24-well	plates	with	increas-
ing	concentrations	(0,	5,	10	µM)	of	STI-571	and	cul-
tured	for	5	days.	Twenty	four	hours	after	seeding,	the	
cells	were	irradiated	at	increasing	doses	(0,	200,	400,	
600	cGY)	with	a	6MV	linear	accelerator	(Varian	600C,	
Palo	Alto,	CA,	USA).	Five	days	after	seeding,	cytotoxic-
ity	was	determined	with	the	SRB	assay	[18].	
To	test	the	combined	effect	of	STI-571	and	cispla-
tin,	the	two	agents	were	added	to	the	culture	medium	
together	for	5	days.	STI-571	(5	or	10	uM)	was	added	
to	0.05	and	0.1	µg/ml	cisplatin	for	experiments	on	the	
SKNMC	line,	and	to	0.05	and	0	.25	µg/ml	cisplatin	for	
experiments	on	the	MCF-7	line.	Cytotoxicity	was	tested	
on	day	5	with	the	SRB	assay.
SrB staining.	In	brief,	the	medium	was	removed,	
and	cold	10%	trichloroacetic	acid	(TCA)	was	added	for	
1	h	at	4	°C.	The	TCA	was	then	removed,	and	the	plates	
were	rinsed	with	water	and	stained	with	SRB,	4	mg/ml	
in	1%	acetic	acid,	as	described	[12].	The	bound	SRB	
was	solubilized	in	1	ml	of	10	mM unbuffered	Tris	solu-
tion.	Thereafter,	100	µl	of	each	sample	were	transferred	
to	a	96-well	plate	and	read	at	550	nm	with	a	microtiter	
ELISA	reader.	The	results	were	expressed	as	percent-
age	of	the	control.
Calculation.	The	 inhibitory	effect	of	each	agent	
added	to	the	cultures	was	calculated	as	follows:	 In-
hibition	(%)	=	[1-(SRB	staining	in	treated	wells/SRB	
staining	in	control	wells)]	X100.
The	 theoretical	 additive	 inhibitory	effect	of	 the	
agents	a	 and	b	was	calculcated	using	 the	 follow-
ing	equation:	 Iab	=100	x	 [1-(1-Ia/100)	x	 (1-Ib/100)]	
where	 Iab is	 the	calculated	additive	 inhibitory	effect	
expressed	as	%	inhibition. Ia and Ib are	the	measured	
inhibitory	effects	(%)	of	each	agent	acting	alone	as	
compared	with that	of	the	control	cultures.	This	equa-
tion	was	derived	assuming	the	 inhibitory	agents	act	
independently	on	the	same	target	population	[19].
Western blot.	Phosphorylated	AKT	was	detected	
in	 the	cells	after	 induction	with	FCS	as	 follows.	Cells	
(1	x	106/dish)	were	grown	in	serum-deprived	RPMI	1640	
for	24	h.	STI-571	was	then	added	to	the	culture	for	90	min.	
To	induce	phosphorylation	of	AKT,	FCS	was	added	to	the	
cell	cultures	for	1	h.	Cells	were	then	harvested,	washed	
with	PBS	and	lysed	with	the	CHAPS	lysis	buffer	(10	mM	
Tris-HCl,	pH	7.5,	1	mM	MgCl2,	1	mM	EGTA,	0.1	mM	ben-
zamidine,	5mM	β-mercaptoethanol,	0.5%	3-[(3-chol-
amidopropyl)-dimethyl-	ammonio]-1-propanesulfonate,	
10%	glycerol).	Protein	concentration	was	determined	
using	the	Bradford	assay	(Bio-Rad	Laboratories,	Her-
cules,	CA,	USA).	Equal	protein	amounts	of	all	samples	
(20–40	µg)	were	resolved	on	10%	sodium	dodecylsulfate	
(SDS)	and	transferred	to	a	polyacrylamide	gel	and	then	
to	a	polyvinylidene	difluoride	(PVDF)	membrane.	The	AKT	
protein	or	its	phosphorylated	form	was	detected	with	a	
specific	monoclonal	antibody	(Cell	Signaling	Technology,	
Beverly,	MA)	in	1	:	1000	dilution,	followed	by	horserad-
ish	peroxidase-conjugated	goat-anti-rabbit	antibody	
(Jackson	Laboratories,	West	Grove,	PA,	USA).	The	
SuperSignal®West	Pico	Chemiluminiscent	Substrate	kit	
(Pierce,	IL,	USA)	was	used	to	visualize	the	expression	of	
both	proteins,	according	to	the	manufacturer’s	protocol.	
Signals	were	quantified	using	Quantity–One	software	for	
Bio-Rad	image	analysis	systems	(Bio-Rad	Laboratories).	
Phosphorylated	AKT	expression	was	calculated	relative	
to	the	total	signal	obtained	from	the	AKT	protein.	
Apoptosis assay.	Cells	(1.5	x	104/ml)	were	seeded	
in	a	24-well	plate	and	treated	with	STI-571	10	or	15	µM,	
cisplatin	0.1	µg/ml,	and	 radiation	400	cGY,	alone	or	
in	combination.	DNA	fragmentation	was	determined	
by	nucleosome	assessment	using	a	commercial	Cell	
Death	ELISA	Plus	kit	(Roche,	Mannheim,	Germany),	
according	 to	 the	manufacturer’s	 instructions.	Cell	
content	was	estimated	in	identical	plates	using	the	SRB	
method.	The	data	obtained	by	ELISA	were	normalized	
for	cell	content;	the	apoptotic	index	was	calculated	as	
percentage	of	the	untreated	controls.
Statistical analysis. The	data	are	presented	as	
mean	± SD.	Each	experiment	was	performed	at	 least	
three	times.	The	data	were	analyzed	with	two-way	analy-
sis	of	variance	(ANOVA)	using	SPSS software.	A	p	value	of	
less	than	0.05	was	considered	statistically	significant.
results
Effect of Sti-571 on cell proliferation and 
apoptosis. Incubation	of	the	SKNMC	or	MCF-7	cells	in	
the	presence	of	increasing	concentrations	of	STI-571	
for	5	days	resulted	in	a	concentration-dependent	de-
crease	in	cell	number.	
The	concentration	of	STI-571	required	to	cause	a	
50%	decrease	in	cell	number	(IC50)	was	about	15	µM	
for	the	SKNMC	line	and	20	µM	for	the	MCF7	line. As	
the	dose	 increased,	 the	 sensitivity	 of	 the	SKNMC	
cells	to	STI-571	increased	compared	to	the	sensitivity	
of	the	MCF-7	cells	(Fig.	1).	Therefore,	further	evalua-
tion	of	apoptosis	and	analysis	of	the	cell	cycle	were	
performed	on	SKNMC	cells	only.	
The	data	in	the	Table	show	that	STI-571	had	only	a	
negligible	effect	on	the	apoptotic	index. 
Effect of Sti-571 on phosphorylated AKt le-
vels. The	levels	of	AKT	protein	previously	reported	to	
be	involved	in	enhancing	cell	proliferation,	inhibiting	
apoptosis,	and	contributing	 to	 radioresistance	were	
evaluated	by	Western	blot	analysis. 
As	shown	in	Fig.	2,	phosphorylated	AKT	decreased	
dramatically	by	72%	after	90	min	exposure	of	SKNMC	
to	15	µM	STI-571,	as	it	has	recently	been	reported	by	
us,	while	exploring	 regulation	of	 telomerase	activity	
by	STI-571	[20].
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fig. 1. Effect	of	STI-571	on	SKNMC	and	MCF-7	Cells.	SKNMC	
and	MCF-7	cells	(1.5	x	104/ml)	were	incubated	in	the	presence	
of	increasing	concentrations	of	STI-571,	as	described	in	Mate-
rial	and	Methods.	The	surviving	fraction	of	SKNMC	and	MCF-7	
cell	 lines	was	determined	with	 the	sulforhodamine-B	staining	
method.	Values	 represent	mean	±	SD	of	 three	 independent	
experiments,	each	performed	in	quadruplicate	
fig. 2. Phosphorylated	AKT	expression	in	response	to	STI-571	
treatment.	Phosphorylated	AKT	and	total	AKT	protein	levels	after	
SKNMC	exposure	to	15	uM	STI-571	were	analyzed	by	Western	
blot,	as	described	in	Material	and	Methods.	The	figure	depicts	
one	representative	experiment	(out	of	3)
fig. 3. Effect	of	radiation	on	SKNMC	and	MCF-7	Cells.	SKNMC	
and	MCF-7	cells	(1.5	x	104/ml)	were	incubated	in	the	presence	
of	increasing	concentrations	of	STI-571,	as	described	in	Mate-
rial	and	Methods.	The	surviving	fraction	of	SKNMC	and	MCF-7	
cell	 lines	was	determined	by	SRB	staining.	Values	 represent	
mean	±	SD	of	three	independent	experiments,	each	performed	
in	quadruplicate
Exposure of SKnMC and MCF-7 cells to com-
bination of Sti-571 and radiation. Fig.	3	 shows	
the	effect	of	radiation	alone	on	SKNMC	and	MCF-7	
cancer	cells,	and	Fig.	4	and	5	show	the	effect	of	the	
combination	of	STI-571	and	radiation.	Combined	treat-
ment	resulted	in	an	additive	decrease	in	cell	number,	
confirmed	by	two-way	ANOVA.	This	effect	was	more	
pronounced	 in	 the	SKNMC	 than	 the	MCF-7	cells.	
Radiation	induced	a	marked	increase	in	the	apoptotic	
index	of	SKNMC	cells.	The	addition	of	STI-571	did	not	
augment	the	apoptotic	effect	of	radiation	(Table).
Table.	Effect of STI-571, cisplatin, radiation and their combination on the 
apoptotic index of SKNMC cells*
Modalities alone or combined* Apoptotic index (%) 
Control 1
STI-571 10 µM 1.19
STI-571 15 µM 1.28
Cisplatin 0.1 µg/ml 1.27
STI 10 µM cisplatin 0.1 µg/ml 1.78
400 cGY 4.1
STI 10 µM + 400 cGY 3.99
*Cells were treated with STI-571 10 and 15 µM, cisplatin 0.1 µg/ml and ir-
radiation of 400 cGY, alone or in combination. Cells were seeded in a 24-well 
plate, and DNA fragmentation was determined by nucleosome assessment 
using a commercial Cell Death ELISA Plus kit. 
fig. 4. Combined	effect	of	STI-571	and	radiation	on	SKNMC	
cell	line.	Cells	(1.5	x	104/ml)	were	incubated	with	5	and	10	uM	
STI-571.	Twenty-four	hours	after	seeding,	the	treated	and	un-
treated	cells	were	irradiated	at	increasing	doses	(0,	200,	400,	
600	cGY)	with	a	6MV	linear	accelerator.	The	surviving	fraction	
of	SKNMC	cell	 lines	was	determined	by	SRB	staining.	Values	
represent	mean	±	SD	of	three	independent	experiments	,	each	
performed	 in	quadruplicate.	 (a)	5	µM	STI-571	and	200	cGY;	
(b)	5	µM	STI-571	and	400	cGY;	(c)	5	µM	STI-571	and	600	cGY;	
(d)	10	µM	STI-571	and	200	cGY;	(e)	10	µM	STI-571	and	400	cGY;	
(f)	10	µM	STI-571	and	600	cGY	
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fig. 5. Combined	effect	of	STI-571	and	radiation	on	MCF-7	cell	
line.	Cells	 (1.5	x	104/ml)	were	 incubated	with	10	uM	STI-571.	
Twenty-four	hours	after	seeding,	the	treated	and	untreated	cells	
were	irradiated	at	increasing	doses	(0,	200,	400,	600	cGY)	with	a	
6MV	linear	accelerator.	The	surviving	fraction	of	SKNMC	and	MCF-
7	cell	 lines	was	determined	by	SRB	staining.	Values	represent	
mean	±	SD	of	three	independent	experiments,	each	performed	in	
quadruplicate.	(a)	10	µM	STI-571	and	200	cGY;	(b)	10	µM	STI-571	
and	400	cGY;	(c)	10	µM	STI-571	and	600	cGY
Exposure of SKnMC and MCF-7 cells to Sti-571 
and cisplatin. Incubation	of	 the	SKNMC	or	MCF-7	
cells	in	the	presence	of	increasing	concentrations	of	
cisplatin	 resulted	 in	a	concentration-dependent	de-
crease	in	cell	survival.	The	concentration	of	cisplatin	
required	to	inhibit	50%	cell	growth	(IC50)	was	found	
to	be	around	0.35	µg/ml	for	the	MCF-7	cell	line	and	
0.09	µg/ml	for	the	SKNMC	cell	line.
Incubation	of	the	SKNMC	and	MCF-7	cells	in	the	
presence	of	combined	STI-571	and	cisplatin	for	5	days	
yielded	an	additive	cell-killing	effect	on	both	cell	lines	
(Fig.	6,	7),	with	only	a	 slight	 increase	 in	apoptosis	
compared	to	each	agent	alone	(Table).	
disCussion
To	 improve	 the	outcome	of	 radiation	 treatment,	
clinicians	combine	 its	use	with	 standard	cytotoxic	
chemotherapeutic	agents.	Since	the	 introduction	of	
novel	anticancer	drugs	to	the	daily	treatment	arma-
mentarium,	researchers	have	been	seeking	data	on	
the	potential	benefits	of	their	interaction	with	standard	
treatment	modalities.	The	present	study	shows	 that	
STI-571	and	radiation	have	an	additive	antiproliferative	
effect	on	SKNMC	and	MCF-7	human	solid	tumor	cell	
lines.	The	 results	are	 in	accordance	with	 the	 report	
of	Topaly	et	al.	[4]	who	found	a	synergistic	effect	of	
STI-571	and	 radiation	 in	BCR-Abl-positive	 lymphoid	
and	myeloid	blast	crisis	cells.	However	the	Abl	family	
proteins	are	non	receptor	tyrosine	kinase	and	different	
intracellular	mechanisms	may	be	involved.
fig. 6. Combined	effect	of	STI-571	and	cisplatin	on	SKNMC	cell	
line.	STI-571	at	concentrations	of	5	and	10	uM	was	added	to	0.05	
and	0.1	µg/ml	cisplatin.	(a)	5	uM	STI-571	and	0.05	ug/ml	cisplatin;	
(b)	5	uM	STI-571	and	0.1	ug/ml	cisplatin;	(c)	10	uM	STI-571	and	
0.05	ug/ml	cisplatin;	(d)	10	uM	STI-571	and	0.1	ug/ml	cisplatin.	
The	surviving	fraction	was	determined	by	SRB	staining.	Values	
represent	mean	±	SD	of	five	independent	experiments
fig. 7. Combined	effect	of	STI-571	and	cisplatin	on	MCF-7	cell	
line.	STI-571	at	concentrations	of	5	and	10	uM	was	added	 to	
0.05	and	0.25	µg/ml	cisplatin.	(a)	5	uM	STI-571	and	0.05	ug/ml	
cisplatin;	(b)	5	uM	STI-571	and	0.25	ug/ml	cisplatin;	(c)	10	uM	STI-
571	and	0.05	ug/ml	cisplatin;	(d)	10	uM	STI-571	and	0.25	ug/ml	
cisplatin.	The	surviving	fraction	was	determined	by	SRB	staining.	
Values	represent	mean	±	SD	of	five	independent	experiments
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Since	AKT	plays	a	major	role	in	the	PI3	kinase	signal	
transduction	pathway,	and	also	largely	contributes	to	
radioresistance,	we	sought	to	determine	the	effect	of	
combined	treatment	on	levels	of	phosphorylated	AKT	
(the	active	form	of	AKT).	We	noted	a	marked	decrease	
in	phosphorylated	AKT	 following	STI-571	 treatment	
of	SKNMC	cells.	Our	data	are	in	accordance	with	the	
report	of	Ohashi	et	al.	[21]	who	found	a	reduction	in	
phosphorylated	AKT	and	 its	downstream	 targets	 in	
cells	expressing	mutant	platelet-derived	growth	factor	
receptor-alpha.
We	speculate	that	the	inhibition	of	these	pathways	
may	have	contributed	to	the	additive	antiproliferative	
effect	of	STI-571	and	radiation.	In	light	of	findings	that	
p-AKT	inhibits	apoptosis,	we	checked	apoptosis	in	the	
SKNMC	cell	line;	however,	no	significant	contribution	
of	the	drug	to	apoptotic	death	was	detected.	These	
results	suggest	that	STI-571	is	cytostatic	rather	than	
cytotoxic	to	SKNMC	cells,	and	join	previous	findings	of	
a	possible	cytostatic	character	of	STI-571	[22,	23].
The	cell	response	to	irradiation	is	affected	by	the	
cell	cycle	phase.	The	mitotic	phase	is	the	most	sensi-
tive,	followed	by	the	G2	phase.	Resistance	to	radiation	
gradually	increases	as	the	cells	proceed	through	the	
late	G1	and	S	phases,	reaching	a	maximum	in	the	late	
S	phase.	In	cells	with	a	long	G1	phase,	a	peak	of	re-
sistance	is	seen	early	in	G1	[24,	25]. Our	earlier	study	
showed	that	4	days	of	treatment	of	cells	with	15	µM	
STI-571	resulted	in	a	fivefold	increase	in	the	percent	
of	cells	in	G2/M	phase	(15%	vs	3.26%,	p	=	0.0013).	
This	 increase	was	accompanied	by	a	concomitant	
decrease	in	cells	in	the	S	phase,	from	36.5%	to	26.9%	
(p	=	0.0029)	[20].	
On	the	basis	of	these	data,	we	examined	the	influ-
ence	of	STI-571	on	the	cell	cycle.	Our	study	revealed	
that	within	24	h	of	incubation	—	the	time	at	which	we	
irradiated	the	cells	—	STI-571	had	no	influence	on	the	
cell	cycle.	There	was,	however,	a	small	but	significant	
increase	in	the	G2	/M	phase	4	days	after	incubation	with	
STI-571	[20].	Further	evaluation	of	the	effect	of	cell	ir-
radiation	4	days	after	incubation	with	STI-571	yielded	
no	significant	improvement	in	inhibition	of	cell	growth	
as	compared	to	radiation	24	h	after	incubation.	
Cisplatin	is	a	major	drug	in	the	treatment	of	malig-
nancy.	Our	study	showed	that	the	addition	of	a	novel	
drug	 to	an	 “old”	one	augments	cell	death.	Accord-
ingly,	it	was	reported	that	the	combination	of	STI-571	
and	cisplatin	synergistically	inhibited	lung	[1]	or	head	
and	neck	[27,	28]	cancer	cell	growth.	Regardless	of	
whether	their	action	is	additive	or	synergistic,	STI-571	
and	cisplatin	do	not	interfere	with	each	other’s	antipro-
liferative	effect	on	breast	cancer	and	Ewing’s	sarcoma	
as	was	observed	in	our	experiments.	
These	promising	preliminary	findings	may	have	im-
portant	implications	for	the	treatment	of	various	types	
of	cancer	and	should	support	conducting	clinical	trials	
with	this	new	agent	[29].	Further	studies	are	needed	
to	corroborate	the	benefit	of	combining	STI-571	with	
standard	modalities.
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антипролиферативная активность иматиниба (sti-571) 
в комбинации с облучением или цисплатиной in vitro 
Цель: оценить антипролиферативный эффект иматиниба (STI-571) в комбинации �� обл��ением или ци��платиной по отно�е-        
нию к дв�м клето�ным линиям – клеткам линии SKNMC, пол��енным и�� ��аркомы �вин�а, и клеткам рака моло�ной �еле��ы          
�еловека линии MCF-7. Методы: для оценки пролиферации клеток применяли метод анали��а цитоток��и�но��ти �� и��поль��о-
ванием ���льфородамина B. �ля анали��а ра��пределения клеток по фа��ам клето�но�о цикла применяли метод прото�ной цито-            
метрии, апопто��а – �� применением коммер�е��ко�о набора для проведения ИФА. Уровень фо��форилированной кина��ы АКТ, 
предполо�ительно ��вя��анной �� радиоре��и��тентно��тью, определяли методом Ве��терн-блот анали��а. Результаты: инк�бация 
клеток SKNMC �� STI-571 приводила к до��о��ави��имом� антипролиферативном� эффект� и ��ни�ению фо��форилирования           
AKT, но не апопто��� клеток. Комбинированное применение STI-571 и обл��ения или ци��платины ока��ывало дополнительное              
антипролиферативное во��дей��твие на клетки линии SKNMC (60% �мень�ения коли�е��тва клеток). Анало�и�ные эффекты       
отме�али на клетках линии MCF-7. Выводы: обработка оп�холевых клеток STI-571 ���иливает эффект обл��ения и ци��-     
платины in vitro , при�ем таковой мо�ет быть опо��редован ��и�нальным ка��кадом AKT.
Ключевые слова: STI-571, �ливек, иматиниб, обл��ение, ци��платина, клето�ный цикл, фо��форилированная AKT, апопто��.         
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